Completed
A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States
NCT07757048· Novartis Pharmaceuticals· Source
Completed
A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy
NCT07403214· Novartis Pharmaceuticals· Source
Completed
A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients
NCT07805408· Novartis Pharmaceuticals· Source
Completed
A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse
NCT07743281· Novartis Pharmaceuticals· Source
Completed
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients
NCT07760714· Novartis Pharmaceuticals· Source
Completed
A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
NCT07409636· Novartis Pharmaceuticals· Source
Completed
A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies
NCT07378943· Novartis Pharmaceuticals· Source
Completed
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
NCT07566988· Novartis Pharmaceuticals· Source
Completed
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
NCT07512063· Novartis Pharmaceuticals· Source
Completed
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
NCT07477756· Novartis Pharmaceuticals· Source
Completed
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
NCT06595069· Novartis· Source
Completed
A Study of Real-world Outcomes Among Patients Treated With Ribociclib
NCT07148505· Novartis Pharmaceuticals· Source
Completed
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
NCT07168694· Novartis Pharmaceuticals· Source
Completed
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
NCT07151820· Novartis Pharmaceuticals· Source
Completed
Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal
NCT07223476· Novartis Pharmaceuticals· Source
Completed
A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure
NCT07217106· Novartis Pharmaceuticals· Source
Completed
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
NCT07188428· Novartis Pharmaceuticals· Source
Completed
A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data
NCT06854341· Novartis Pharmaceuticals· Source
Completed
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
NCT07374120· Novartis Pharmaceuticals· Source
Completed
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
NCT06897657· Novartis Pharmaceuticals· Source
Completed
Effectiveness of Ofatumumab in Real-world Practice
NCT06760624· Novartis Pharmaceuticals· Source
Completed
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
NCT07376265· Novartis Pharmaceuticals· Source
Completed
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
NCT07450157· Novartis Pharmaceuticals· Source
Completed
A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia
NCT07415083· Novartis Pharmaceuticals· Source
Completed
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
NCT06692803· Novartis Pharmaceuticals· Source
Completed
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
NCT07039383· Novartis Pharmaceuticals· Source
Completed
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
NCT06604897· Novartis Pharmaceuticals· Source
Completed
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
NCT07023445· Novartis Pharmaceuticals· Source
Completed
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
NCT07363434· Novartis Pharmaceuticals· Source
Completed
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06699914· Novartis Pharmaceuticals· Source
Terminated
A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
NCT06715254· Novartis Pharmaceuticals· Source
Completed
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
NCT06991894· Novartis Pharmaceuticals· Source
Completed
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
NCT06737419· Novartis Pharmaceuticals· Source